Department of Pharmacy, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia.
Department of Physiology, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia.
Heart Fail Rev. 2021 Mar;26(2):437-450. doi: 10.1007/s10741-020-10005-5.
Previous studies have demonstrated that individuals with type 2 diabetes mellitus (T2DM) have a two- to fourfold propensity to develop cardiovascular disease (CVD) than nondiabetic population, making CVD a major cause of death and disability among people with T2DM. The present treatment options for management of diabetes propose the earlier and more frequent use of new antidiabetic drugs that could control hyperglycaemia and reduce the risk of cardiovascular events. Findings from basic and clinical studies pointed out DPP-4 inhibitors as potentially novel pharmacological tools for cardioprotection. There is a growing body of evidence suggesting that these drugs have ability to protect the heart against acute ischaemia-reperfusion injury as well as reduce the size of infarction. Consequently, the prevention of degradation of the incretin hormones by the use of DPP-4 inhibitors represents a new strategy in the treatment of patients with T2DM and reduction of CV events in these patients. Here, we discuss the cardioprotective effects of DPP-4 inhibitors as well as proposed pathways that these hypoglycaemic agents target in the cardiovascular system.
先前的研究表明，2 型糖尿病（T2DM）患者发生心血管疾病（CVD）的倾向是无糖尿病人群的两到四倍，使 CVD 成为 T2DM 患者死亡和残疾的主要原因。目前用于糖尿病管理的治疗方案建议更早、更频繁地使用新的抗糖尿病药物，以控制高血糖并降低心血管事件的风险。基础和临床研究的结果指出，DPP-4 抑制剂可能是心脏保护的新型药理学工具。越来越多的证据表明，这些药物具有保护心脏免受急性缺血再灌注损伤以及减少梗塞面积的能力。因此，通过使用 DPP-4 抑制剂来防止肠促胰岛素激素的降解代表了治疗 T2DM 患者和减少这些患者心血管事件的一种新策略。在这里，我们讨论了 DPP-4 抑制剂的心脏保护作用以及这些降血糖药物在心血管系统中的作用途径。
